Resistant dextrin increases fecal Parabacteroides in high- and low-fiber diet adults: double-blind pilot RCT
Four weeks of resistant dextrin 15 g/day raised Parabacteroides relative abundance from ~1.4% to 5.5% versus placebo stable at 1.4% (p < 0.0001), with no detectable effect on SCFAs, fecal pH, secretory IgA, or stool consistency.
Context
Dietary fiber intake in high-income countries chronically falls below recommendations, negatively affecting gut microbiome composition. Supplementation with fermentable soluble fibers is investigated as a practical approach for populations unwilling to change diet. Assessing whether the prebiotic effect of resistant dextrin is modified by baseline dietary fiber level is clinically relevant for personalizing recommendations.
What the study showed
Parabacteroides relative abundance increased from ~1.3–1.5% at baseline to 5.5% in the active group vs. remaining at ~1.3–1.4% with placebo, in both the total population and HF/LF subgroups (all p < 0.0001). P. distasonis reached 2.6% vs. 0.5% with placebo (p < 0.0001). The effect reversed within 2 weeks post-intervention. Bacillota phylum showed a non-significant trend toward reduction (55.4% vs. 59.0%; p = 0.0545). No effect was detected on fecal pH, total SCFAs, secretory IgA, stool consistency, or frequency (all p > 0.05).
How it was done
Randomized, double-blind, placebo-controlled pilot trial with 4 weeks of intervention and 2 weeks of post-intervention follow-up. Total of 124 participants (62 per arm); exclusively healthy normal-weight adult men. Microbiome assessed by sequencing (functional metagenomics also reported); fecal outcomes measured at baseline, end of intervention, and end of follow-up.
Effect magnitude
Absolute difference in Parabacteroides: +4.1 percentage points of relative abundance (from ~1.4% to 5.5%) in the active group vs. stable ~1.4% with placebo (p < 0.0001); 95% CI not reported in the available summary. For P. distasonis: 2.6% vs. 0.5% (difference 2.1 pp; p < 0.0001); formal effect sizes (OR, SMD) were not reported.
Limitations
Pilot study with an exclusively male sample limits generalizability to women and other populations. Absence of 95% CIs and standardized effect sizes hampers meta-analytic comparisons. The primary outcome (Parabacteroides relative abundance) is an intermediate marker without established correlation with clinical outcomes. Four-week duration is insufficient to assess effect persistence. Industry funding (NUTRIOSE® is a Roquette product) represents sponsorship bias risk; RoB 2 tool not mentioned in the available text. The reversibility of the effect within 2 weeks questions the clinical sustainability of the intervention.
In clinical practice
Resistant dextrin at 15 g/day for 4 weeks modifies fecal bacterial composition in healthy men regardless of baseline dietary fiber level, but without demonstrated translation into functional (SCFAs, pH, IgA) or symptomatic outcomes. Clinicians should not recommend this supplement for clinical purposes based solely on this study. Current evidence supports use only in research contexts or as an exploratory adjunct in populations with low fiber intake.
What is still missing
Studies in mixed-sex populations, with primary clinical outcomes (metabolic syndrome, inflammation, bowel function), duration ≥ 12 weeks, and dose-response assessment are needed to establish clinical relevance. The causal relationship between increased Parabacteroides and measurable health benefits requires investigation.